Longitudinal evaluation of EGFR mutation in plasma for non-small cell lung cancer patients with front-line chemotherapy

被引：0
|
作者：
Hua, B. [1 ]
Zhao, J. [1 ]
Wang, S. H. [1 ]
Yang, L. [1 ]
Duan, J. C. [1 ]
Wu, M. N. [1 ]
Wang, J. [1 ]
机构：
[1] Beijing Tumor Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8099
引用
收藏
页数：1
相关论文
共 50 条
  • [1] EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer
    Wu, Meina
    Zhao, Jun
    Song, Sonya Wei
    Zhuo, Minglei
    Wang, Xin
    Bai, Hua
    Wang, Shuhang
    Yang, Lu
    An, Tongtong
    Zhang, Yan
    Duan, Jianchun
    Wang, Yuyan
    Guo, Qingzhi
    Liu, Xuyi
    Liu, Ninghong
    Wang, Jie
    LUNG CANCER, 2010, 67 (03) : 343 - 347
  • [2] Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status
    Kalikaki, Aristea
    Koutsopoulos, Anastasios
    Hatzidaki, Dora
    Trypaki, Maria
    Kontopodis, Emmanouel
    Stathopoulos, Efstathios
    Mavroudis, Dimitris
    Georgoulias, Vassilis
    Voutsina, Alexandra
    LUNG CANCER, 2010, 69 (01) : 110 - 115
  • [3] Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC)
    Ferrigno, D
    Buccheri, G
    LUNG CANCER, 2004, 45 (03) : 373 - 380
  • [4] Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy
    Besse, B
    Soria, JC
    Le Chevalier, T
    ANNALS OF ONCOLOGY, 2005, 16 (07) : 997 - 998
  • [5] FRONT-LINE CHEMOTHERAPY WITH OR WITHOUT NGR-HTNF IN NON-SMALL CELL LUNG CANCER (NSCLC)
    Gregorc, V.
    Zilembo, N.
    Grossi, F.
    De Pas, T.
    Pietrantonio, F.
    Giovannini, M.
    Rossoni, G.
    Bulotta, A.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 410 - 410
  • [6] Radium-223 following front-line chemotherapy for patients with non-small cell lung cancer and bone metastases
    Taber, Angela Marie
    Riley, David
    Olszewski, Adam J.
    Birnbaum, Ariel E.
    Khurshid, Humera
    Yoo, Don
    Noto, Richard
    Rosati, Kayla
    Safran, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Evaluation of EGFR mutation testing in plasma from non-small cell lung cancer (NSCLC) patients
    Gonzalez De Aledo-Castillo, J. M.
    Victoria, I.
    Arcocha, A.
    Reguart, N.
    Molina Porto, R.
    Puig-Butille, J. A.
    CLINICA CHIMICA ACTA, 2019, 493 : S570 - S570
  • [8] The Cost and the Benefit: Front-Line Immunotherapy for Non-Small Cell Lung Cancer
    Bestvina, C. M.
    Vokes, E. E.
    Hoffman, P. C.
    Patel, J. D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1552 - S1552
  • [9] Effect of chemotherapy on EGFR mutation status in Chinese non-small cell lung cancer patients
    Wang, J.
    Bai, H.
    Zhao, J.
    Wang, Z.
    Zhuo, W.
    Wu, M.
    Duan, J.
    Wang, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer
    Kim, Jeong-Oh
    Shin, Jung-Young
    Kim, Seo Ree
    Shin, Kab Soo
    Kim, Joori
    Kim, Min-Young
    Lee, Mi-Ran
    Kim, Yonggoo
    Kim, Myungshin
    Hong, Sook Hee
    Kang, Jin Hyoung
    CANCERS, 2020, 12 (04)
12345